Page 2 - Hartmut Ehrlich News Today

Feedback received from the US and European regulatory agencies, both supporting the advancement ABX464 into a phase 3 clinical program in ulcerative colitis (UC), final preparations for the launch of the

Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces its... | March 16, 2022

Once-daily oral treatment was well-tolerated and demonstrated a good safety profile in Phase IIb study - News - PharmaTimes

Abivax’s COVID-19 study declared Research National Priority by French government Drug treatment is being investigated in high-risk COVID-19 patients Abivax’s COVID-19 study evaluating its anti-inflammatory candidate ABX464 has been deemed a ‘research national priority’ by a French government steering committee. The steering committee for therapeutic clinical trials and other research (CAPNET) was created by the French government to identify promising and impactful COVID-19 clinical tri...